Mental Health

Coffee Consumption May Reduce Depression Risk and Boost Mood, Offering Potential Benefits for Mental Health

The research further emphasizes the need for more attention on both chronic kidney disease (CKD) and mental health conditions.

As an adjunct to depression treatment, lumateperone reduced depressive symptoms and improved quality of life.

Explore the risks of synthetic 7-hydroxymitragynine (7-OH) products and why natural leaf kratom is a safe alternative.

Explore how pharmacist-led long-acting injectables (LAIs) enhance medical adherence for schizophrenia patients, improving care transitions and outcomes.

Long-term benzodiazepine use has been linked to lasting cognitive impairments, underscoring the vital role pharmacists play in supporting safe deprescribing strategies.

Rajinder Shiwach, MD, MRCPsych, outlines how pharmacists can strengthen retention, patient education, and access to rapid induction strategies for opioid use disorder treatment.

Heavy workloads, lack of recognition, and stressful environments fuel emotional exhaustion, turnover, and patient safety concerns.

Rajinder Shiwach, MD, MRCPsych, discusses how rapid induction with extended-release buprenorphine improves patient retention and maintains comparable efficacy and tolerability to standard induction methods.

A heightened ratio of non-high-density lipoprotein cholesterol (non-HDL-C) to HDL-C was associated with depression, with risk mediated by body mass index.

Further research is needed to better understand which characteristics may better predict who are more likely to benefit from estrogen-based menopausal hormonal therapy (MHT) for anxiety.

Initiatives aim to reduce residents' high rates of depression and increase self-care skills.

Although long COVID remains a complex disease, pharmacists are critical team members for patient symptom validation, managing polypharmacy, and navigating therapy access.

FDA approves Uzedy, an extended-release injectable formulation of risperidone, enhancing treatment options for adults with bipolar I disorder.

Public debate intensifies as Robert F. Kennedy Jr compares selective serotonin reuptake inhibitors (SSRIs) to heroin, prompting mental health experts to clarify antidepressant use and withdrawal misconceptions.

Combining tramadol with CYP2D6-inhibiting antidepressants raises seizure risk in older adults, highlighting the need for careful medication management.

The authors wrote that patients with CKD who are younger than 60 years may be at a greater risk of depression.

Recent studies reveal that simvastatin does not enhance escitalopram's effects in treating depression, despite improving metabolic health in obese patients.

Real-world data from nearly 1.5 million administrations of intranasal esketamine (Spravato) show that its safety profile—including risks of sedation, blood pressure changes, and dissociation—remains consistent with clinical trial findings.

Careful selection of pharmacotherapy and close monitoring are crucial to ensuring safety and efficacy.

Pharmacists are key to closing care gaps and supporting long-term recovery.

Pharmacists enhance patient safety by addressing common medication errors, ensuring proper drug use, and improving therapeutic outcomes in clinical practice.

GLP-1 receptor agonists show promise in alleviating depressive symptoms in patients with type 2 diabetes, offering a potential dual benefit in treatment.

MM120 shows promise in treating generalized anxiety disorder, demonstrating significant symptom relief and a potential shift in psychiatric treatment approaches.